Surprise As FDA Approves Sarepta’s Duchenne Drug Vyondys 53
A Second Controversial Duchenne Approval For Company
The FDA has overcome doubts about the drug's safety and reversed its decision in just four months.
You may also be interested in...
A look back at some of the defining events and trends in pharma over the past 10 years.
The firm reorganized to focus on hemoglobinopathies and cancers after Celgene ended a multi-drug partnership. Also, Flagship funds a gene therapy start-up and brings in a business development veteran, Ultragenyx raises $320m in a royalty deal and Paratek secures up to $285m from BARDA.
After years of failure, expectations of solanezumab are very low – but Lilly still hoping for a signal.